Integrating bulk RNA-seq and scRNA-seq data to explore diverse cell death patterns and develop a programmed cell death-related relapse prediction model in pediatric B-ALL

整合批量RNA测序和单细胞RNA测序数据,探索儿童B细胞急性淋巴细胞白血病(B-ALL)中不同的细胞死亡模式,并构建程序性细胞死亡相关复发预测模型。

阅读:1

Abstract

Acute B-lymphoblastic leukemia (B-ALL) is a hematologic malignancy with diverse mechanisms of PCD influencing its progression. This study aimed to identify PCD-related biomarkers and develop a predictive model for relapse in pediatric B-ALL patients. Initially, we examined the activity of 16 PCD patterns in B-ALL patients using scRNA-seq. Following this, we employed both univariate and multivariate Cox regression analyses to identify relapse-related PCD patterns and constructed a relapse prediction model comprising seven key PCD-related genes: Bcl-2-interacting killer (BIK), translocator protein (TSPO), BCL2L2, PIP4K2C, mixed-lineage kinase-like (MLKL), STAT2, and WW domain-containing oxidoreductase (WWOX). Based on the optimal cut-off value derived from the cell death index(CDI) model, patients were categorized into high-CDI and low-CDI groups. Additionally, we evaluated the association between CDI scores and immune cell infiltration, tumor microenvironment (TME) characteristics, and drug sensitivity. Nine PCD patterns, encompassing ferroptosis, autophagy, necroptosis, entotic cell death, alkaliptosis, apoptosis, netotic cell death, oxeiptosis, and NETosis, exhibited strong associations with relapse in B-cell acute lymphoblastic leukemia (B-ALL). The CDI model, validated across multiple cohorts, demonstrated substantial predictive power for relapse-free survival (RFS) and was identified as an independent risk factor. This study offers a comprehensive analysis of PCD patterns in pediatric B-ALL, yielding valuable insights into potential novel therapeutic strategies and opportunities for personalized treatment approaches.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。